Tempus Buys Personalis for MRD Edge | Raleigh News

Tempus AI just dropped a blockbuster: it’s buying Personalis for $1.5 billion, snapping up a revolutionary cancer test that spots hidden disease before scans ever catch it. The NeXT Personal test, which detects minimal residual disease using tumor DNA fragments, has been a joint effort for three years — now Tempus gets full control and all the revenue. With a $20 billion market and only 10% of eligible patients tested, this is a massive play. Personalis is already booming — $22.4M in Q2 revenue and 33% test volume growth. Beyond the test, Tempus grabs Personalis’s genomic data, fueling big pharma deals like the $200M AstraZeneca pact. But the stock took a hit — mostly because the deal’s paid in new shares, diluting investors, and won’t close until late 2026 or early 2027. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e62b8a9e71be851e